Smith & Nephew Share Discussion Threads

[rock star] 03/5/2018 07:25

Flat earnings and a P/E of 22 hardly makes it remotely attractive. Also I see plenty of alternative wound care therapies coming through in coming years. Look at Origin WW as an example. Technology been given fast track approval by FDA.

[broadwood] 23/4/2018 19:35

I bought these on the bid speculation awhile back.

This sounds interesting.




Smith & Nephew was top of the blue chip pile as Dutch giant Philips' first-quarter results revealed strong growth in medical equipment, which was music to the ears of the London-listed maker of artificial shoulders, knees and possibly toes.

A further tonic for S&N shares was bid speculation bubbling up again as City traders pointed to US-based Stryker, based in the marvellously named Kalamazoo, Michigan, being a possible suitor after four years ago confirming it had been been looking at a potential takeover.

[its the oxman] 23/4/2018 15:48

Why today? News?

[basil brush1] 23/4/2018 15:43

Is this the big breakout?

[basil brush1] 04/4/2018 16:13

Any views on new CEO? He sold Alere to Abbott in 2017 for $5.3 billion. No one seems to care?

[its the oxman] 24/1/2018 08:00

Scope to have a run back over 1300p with lower tax guidance.

[basil brush1] 22/1/2018 10:20

Strykers full results are on Jan 30, the next few weeks will be interesting.


Stryker provides 2017 preliminary net sales results
By GlobeNewswire, January 09, 2018, 08:15:00 AM EDT

Kalamazoo, Michigan - January 9, 2018 - Stryker Corporation (NYSE:SYK) announced today that preliminary results for the fourth quarter and full year 2017 were:

Preliminary Fourth Quarter Highlights

Net sales grew 10.0% to $3.5 billion (8.7% constant currency)

Orthopaedics 8.1 % or 6.8 % constant currency
MedSurg 10.9 % or 9.8 % constant currency
Neurotechnology and Spine 11.5 % or 10.3 % constant currency
Preliminary Full Year Highlights

Net sales grew 9.9% to $12.4 billion (9.8% constant currency)

Orthopaedics 6.6 % or 6.5 % constant currency
MedSurg 13.6 % or 13.4 % constant currency
Neurotechnology and Spine 8.2 % or 8.3 % constant currency
Preliminary consolidated net sales of $3.5 billion and $12.4 billion increased 10.0% and 9.9% as reported in the fourth quarter and full year. Excluding the impact of foreign currency and acquisitions, net sales increased 8.1% and 7.1% in the fourth quarter and full year.

Based on our year-to-date performance, we expect 2017 adjusted net earnings per diluted share(a) to be toward the high end of our previously announced range of $6.45 to $6.50. The foreign currency exchange impact on net sales in the fourth quarter was positive of approximately 1.2% and nominal in the full year.

"We continued our momentum with strong organic sales growth of 8% for the fourth quarter and 7% for the full year," said Kevin A. Lobo, Chairman and Chief Executive Officer. "I would like to thank our teams for delivering these results, which were well balanced across businesses and geographies. We are also driving innovation through R&D and acquisitions that will fuel future growth. These investments will enable us to deliver sales growth at the high end of med tech and leveraged earning gains."

[basil brush1] 22/1/2018 10:16

Good luck! IMO these UK companies that report in foreign currencies lose out both ways, because the US investors dont understand the accounting while the UK investors are confused by the currency. SN has fallen nearly £2 since October, the market seems to be discounting the worst. But meanwhile Stryker keeps marching on.

[its the oxman] 21/1/2018 12:42

Bloody well hope there is a bid. Sold a load just under 1400p and now bought them back and more besides. Poor performer over 12 months. Hoping for a bounce regardless with results. We will see.

[basil brush1] 19/1/2018 08:39

imo lots of support at 1230. the big question is will there be a bid before the new CEO is appointed? looks vulnerable as share price has not changed in dollar terms in nearly 4 years. Stryker has doubled in the same period.

[pugugly] 18/1/2018 16:25

Could have further to fall (imo)
11-Oct-17Citigroup Sell Now 1,233.50 Then 1,359.00 New target 1,160.00

[basil brush1] 17/1/2018 11:18

these were 1440 less than 3 months back. are the powers than be managing the price down so to get a bid in at not much higher than the October highs?

[its the oxman] 16/1/2018 20:07

As a quality operator surely SN will get some bid speculation this year. Must be so tempting now it's slipped back to 1250p.

[basil brush1] 05/1/2018 12:29

nice to finally see a rally. S&N has underperformed stryker by 75% over two years in dollar terms. S&N ADRs are unchanged while stryker has gone up by 75%. unbelievable.

[basil brush1] 02/1/2018 21:54

this is a real dog stock. having tracked stryker closely for decades, this has incredibly under-performed by a massive 75% in the last two years. three years ago stryker was only slightly bigger than S&N, now it is four times the size.

[basil brush1] 15/12/2017 14:05

Anyone know why these are trading at such a big discount to Stryker? Is it because SN does not have enough debt on board? I have SN on a PE ratio of 18 from Google Finance, with SYK at 35.

[basil brush1] 13/12/2017 14:58

these shares seem to have dodgy knees.... anyone know what happened with Elliot Advisors?

[its the oxman] 13/11/2017 12:15

Dodgy knees and hips aren't going away - keep buying.

[quant_investor] 03/11/2017 16:26

Looking for a safe home for some funds. Nice chart, reasonable valuation, defensive sector all looks nice.

Update this morning states "Full year outlook at the lower end of guidance range" yet the shares are up over 2.0%.

Can only assume the market is impressed by the CEO's buy which isn't particularly large for someone running a multi-billion pound company.

Think I'll keep an eye on broker forecasts for now.

[3rd eye] 27/10/2017 10:20

SN. Smith @Nephew..reports on 3rd of November and im expecting share price to chase upwards to that date. Gap up at open on verge of 5 year breakout.

[3rd eye] 13/10/2017 12:58

S @ N Smith @ Nephew..............

[edwardt] 12/10/2017 12:58

inference was they have only got 0.5% but as you say nobody knows and it is definitely under 3% disclosable. if I was them, I would not be happy if they were building a stake.

[steeplejack] 12/10/2017 08:01

Lot of discussion on FTs Alphaville yesterday.S&N figures coming up Nov 3rd,could be weak given hurricanes that have interrupted Florida hip replacement market.Doing various calculations,a target price of £17-80 is mentioned,this in the event of a bid I presume.Natter about breaking up Smith and Nephew.Johnson&Johnson and Stryker mentioned as perennial takeover possibles.Just what stake Eliott have taken remains unknown for now.

[edwardt] 11/10/2017 13:58

perhaps sell it to vest his options before he goes - I know that is what I would be thinking :)

[steeplejack] 11/10/2017 12:18

He's not going til the end of 2018 by which time he'll be in his 60th year.Happy retirement.